Restless Legs Syndrome – Pipeline Review, H1 2016
Global Markets Direct’s, ‘Restless Legs Syndrome – Pipeline Review, H1 2016’, provides an overview of the Restless Legs Syndrome pipeline landscape. The report provides comprehensive information on the therapeutics under development for Restless Legs Syndrome, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of ………
Total Pages: 45
Global Markets Direct’s, ‘Restless Legs Syndrome - Pipeline Review, H1 2016’, provides an overview of the Restless Legs Syndrome pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Restless Legs Syndrome, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Restless Legs Syndrome and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape of Restless Legs Syndrome
- The report reviews pipeline therapeutics for Restless Legs Syndrome by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Restless Legs Syndrome therapeutics and enlists all their major and minor projects
- The report assesses Restless Legs Syndrome therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Restless Legs Syndrome
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Restless Legs Syndrome
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Restless Legs Syndrome pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Restless Legs Syndrome Overview 6
Therapeutics Development 7
Pipeline Products for Restless Legs Syndrome - Overview 7
Restless Legs Syndrome - Therapeutics under Development by Companies 8
Restless Legs Syndrome - Pipeline Products Glance 9
Late Stage Products 9
Clinical Stage Products 10
Early Stage Products 11
Restless Legs Syndrome - Products under Development by Companies 12
Restless Legs Syndrome - Companies Involved in Therapeutics Development 13
Alexza Pharmaceuticals, Inc. 13
Hisamitsu Pharmaceutical Co., Inc. 14
Ligand Pharmaceuticals, Inc. 15
Mundipharma International Ltd 16
Omeros Corporation 17
Vifor Pharma AG 18
Restless Legs Syndrome - Therapeutics Assessment 19
Assessment by Monotherapy Products 19
Assessment by Combination Products 20
Assessment by Target 21
Assessment by Mechanism of Action 23
Assessment by Route of Administration 25
Assessment by Molecule Type 27
Drug Profiles 28
(naloxone hydrochloride + oxycodone hydrochloride) ER - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
aplindore fumarate - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
AZ-008 - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
ferric carboxymaltose - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
OMS-527 - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
ropinirole hydrochloride - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Restless Legs Syndrome - Recent Pipeline Updates 36
Restless Legs Syndrome - Dormant Projects 38
Restless Legs Syndrome - Discontinued Products 39
Restless Legs Syndrome - Product Development Milestones 40
Featured News & Press Releases 40
May 29, 2015: Napp receives approval from MHRA to prescribe Targinact (oxycodone/naloxone) for the treatment of Restless Legs 40
Oct 24, 2014: Mundipharma receives Positive CHMP Opinion for Targin (oxycodone / naloxone) for the treatment of Restless Legs Syndrome 41
Jan 07, 2014: Mundipharma receives positive European Commission decision on Targin (oxycodone/naloxone) for the treatment of Restless Legs Syndrome 41
Nov 19, 2013: New data show efficacy of prolonged release TARGIN (oxycodone / naloxone) in the treatment of severe restless legs syndrome 42
Oct 16, 2008: Neurogen Announces Positive Top-Line Results From Two Phase II Trials For Aplindore In Restless Legs Syndrome And Parkinson's Disease 43
Appendix 44
Methodology 44
Coverage 44
Secondary Research 44
Primary Research 44
Expert Panel Validation 44
Contact Us 44
Disclaimer 45
List of Tables
Number of Products under Development for Restless Legs Syndrome, H1 2016 7
Number of Products under Development by Companies, H1 2016 8
Comparative Analysis by Late Stage Development, H1 2016 9
Comparative Analysis by Clinical Stage Development, H1 2016 10
Comparative Analysis by Early Stage Development, H1 2016 11
Products under Development by Companies, H1 2016 12
Restless Legs Syndrome - Pipeline by Alexza Pharmaceuticals, Inc., H1 2016 13
Restless Legs Syndrome - Pipeline by Hisamitsu Pharmaceutical Co., Inc., H1 2016 14
Restless Legs Syndrome - Pipeline by Ligand Pharmaceuticals, Inc., H1 2016 15
Restless Legs Syndrome - Pipeline by Mundipharma International Ltd, H1 2016 16
Restless Legs Syndrome - Pipeline by Omeros Corporation, H1 2016 17
Restless Legs Syndrome - Pipeline by Vifor Pharma AG, H1 2016 18
Assessment by Monotherapy Products, H1 2016 19
Assessment by Combination Products, H1 2016 20
Number of Products by Stage and Target, H1 2016 22
Number of Products by Stage and Mechanism of Action, H1 2016 24
Number of Products by Stage and Route of Administration, H1 2016 26
Number of Products by Stage and Molecule Type, H1 2016 27
Restless Legs Syndrome Therapeutics - Recent Pipeline Updates, H1 2016 36
Restless Legs Syndrome - Dormant Projects, H1 2016 38
Restless Legs Syndrome - Discontinued Products, H1 2016 39
List of Figures
Number of Products under Development for Restless Legs Syndrome, H1 2016 7
Number of Products under Development by Companies, H1 2016 8
Comparative Analysis by Late Stage Development, H1 2016 9
Comparative Analysis by Early Stage Products, H1 2016 11
Assessment by Monotherapy Products, H1 2016 19
Number of Products by Targets, H1 2016 21
Number of Products by Stage and Targets, H1 2016 21
Number of Products by Mechanism of Actions, H1 2016 23
Number of Products by Stage and Mechanism of Actions, H1 2016 23
Number of Products by Routes of Administration, H1 2016 25
Number of Products by Stage and Routes of Administration, H1 2016 25
Number of Products by Stage and Molecule Types, H1 2016 27
